학술논문
Cardiovascular Risk and Health Among People With Human Immunodeficiency Virus (HIV) Eligible for Primary Prevention: Insights From the REPRIEVE Trial
Document Type
article
Author
Douglas, Pamela S; Umbleja, Triin; Bloomfield, Gerald S; Fichtenbaum, Carl J; Zanni, Markella V; Overton, Edgar T; Fitch, Kathleen V; Kileel, Emma M; Aberg, Judith A; Currier, Judith; Sponseller, Craig A; Melbourne, Kathleen; Avihingsanon, Anchalee; Bustorff, Flavio; Estrada, Vicente; Ruxrungtham, Kiat; Saumoy, Maria; Navar, Ann Marie; Hoffmann, Udo; Ribaudo, Heather J; Grinspoon, Steven
Source
Clinical Infectious Diseases. 73(11)
Subject
Language
Abstract
BackgroundIn addition to traditional cardiovascular (CV) risk factors, antiretroviral therapy, lifestyle, and human immunodeficiency virus (HIV)-related factors may contribute to future CV events in persons with HIV (PWH).MethodsAmong participants in the global REPRIEVE randomized trial, we characterized demographics and HIV characteristics relative to ACC/AHA pooled cohort equations (PCE) for atherosclerotic CV disease predicted risk and CV health evaluated by Life's Simple 7 (LS7; includes smoking, diet, physical activity, body mass index, blood pressure, total cholesterol, and glucose).ResultsAmong 7382 REPRIEVE participants (31% women, 45% Black), the median PCE risk score was 4.5% (lower and upper quartiles Q1, Q3: 2.2, 7.2); 29% had a PCE score